Most multiple sclerosis (MS) patients eventually suffer from mobility impairment, and thus it is critical that walking disability in MS be accurately assessed. The six-minute walk test (6MWT), a reliable MS measure, is traditionally used to determine the distance covered in six minutes using a standard protocol. With the availability of body sensor networks (BSNs), researchers are interested in leveraging BSN data for finding new gait assessment anchors for improved separability performance. Further, current methods for gait assessments are insufficient since assessments are absolute, performed by comparing outcomes to the statistical norms established from diverse patient data despite natural inter-patient variability. For example, walking at a slower pace may be a personal trait rather than a fatigue-induced impact in MS. Thus instead of using actual values, changes in gait features during a 6MWT can be used to draw clinical conclusions and remove inter-subject variability. We use 6MWT gait time series BSN data of MS subjects to determine changes in their gait speed and gait cycle length variance over six minutes. We also determine the relationships between these variables and three subjective assessments, namely functional systems scores, modified fatigue impact scale, and multiple sclerosis walking scale. These relationships are important in order to validate features and make them clinically meaningful for a doctor. In MS, feelings of fatigue can occur more often, and have a greater impact on a subject's daily life. The results show that MS patients who reported high motor-related fatigue slowed down and had high gait cycle length variance in the last minute of the test, in contrast to those on whom fatigue had minimal impact, enhancing the separability between MS subjects of varied disabilities based on their scores. It is also observed that FSS components related to coordination, balance, and physical activities show strong correlation with gait parameters.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/EMBC.2016.7591840 | DOI Listing |
Mitochondrion
December 2024
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS). The etiology of MS remains elusive, with a complex interplay of genetic and environmental factors contributing to its pathogenesis. Recent studies showed mitochondrial DNA (mtDNA) as a potential player in the development and progression of MS.
View Article and Find Full Text PDFMult Scler Relat Disord
December 2024
Laboratory of Nuclear Medicine (LIM43), Department of Radiology and Oncology, Faculdade de Medicina-FMUSP, Universidade de São Paulo, São Paulo 05403-911, SP, Brazil. Electronic address:
Background: Multiple sclerosis (MS) is divided into Relapsing-Remitting (RRMS) and Progressive (PMS) phenotypes, both associated with spinal cord (SC) damage. MS-related disability and SC atrophy are not yet fully understood and can differ across phenotypes. A combined approach using Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) could provide a broader understanding of myelin changes in the cervical SC (CSC) in different MS phenotypes and the associations with disability.
View Article and Find Full Text PDFMult Scler Relat Disord
December 2024
Kahramanmaras Sutcu Imam University, Faculty of Medicine, Department Of Neurology, Onikisubat, Kahramanmaras, Turkey. Electronic address:
Backround: Manual therapy techniques are available for pain management in Multiple Sclerosis (MS); however, the results of neurodynamic mobilization (NM) are not known. The aim of this study was to investigate the effects of NM exercises on pain, muscle strength and upper extremity functions in MS patients.
Methods: Patients aged between 18 and 65 years diagnosed with Relapsing Remitting (RR) MS (n = 31) according to McDonald 2010 diagnostic criteria were included in the study.
J Neuroimmunol
December 2024
Versiti Blood Research Institute, Milwaukee, WI, USA; Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address:
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Smolensk State Medical University, Smolensk, Russia.
Objective: To study the quality of life (QoL) of patients with multiple sclerosis (MS) in the Smolensk region who receive MS disease-modifying therapies (DMT).
Material And Methods: The study included 37 patients receiving MS DMT. The 36-Item Short Form Health Survey (SF-36), the Multiple sclerosis Quality of Life (MusiQol), the Hamilton Depression Rating Scale, a scale of satisfaction with treatment, the Fatigue Severity Scale were administered.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!